Physician profile
Daniel Ghiyam
NPI 1750378188
$6,608.64
in general payments reported to CMS, 2019-2025
38 companies · $1,145 in 2025
The $1,145 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $836 · 2020: $588 · 2021: $1,155 · 2022: $708 · 2023: $1,131 · 2024: $1,047 · 2025: $1,145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,323.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,322.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,443.72 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $789.76 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $588.33 | 2019-2025 | Evenity, Prolia, Otezla |
| Abbvie INC. | $577.06 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $471.88 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Allergan, INC. | $316.29 | 2019-2021 | |
| Merz North America, INC. | $270.94 | 2021-2023 | Xeomin |
| Merck Sharp & Dohme LLC | $236.88 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Glaxosmithkline, LLC. | $186.63 | 2020-2025 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $153.68 | 2019-2024 | Synjardy, Jardiance |
| Pfizer INC. | $148.16 | 2019-2025 | |
| Radius Health, INC. | $144.54 | 2023-2024 | Tymlos |
| Idorsia Pharmaceuticals US INC | $132.30 | 2022-2023 | Quviviq |
| Janssen Pharmaceuticals, INC | $127.43 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $110.43 | 2019-2021 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Ghiyam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.